In KRAS-mutant NSCLC, XPO1 inhibition produces strong synthetic lethal effects by increasing the phosphorylated inhibitory subunit of NF-κB, thereby further suppressing NF-κB activity and promoting apoptosis. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.